Pfizer tests Next-Gen flu shot using mRNA tech
NCT ID NCT06179446
Summary
This study tested the safety and immune response of a new mRNA vaccine designed to protect against pandemic influenza strains. Healthy adults received either the experimental vaccine, a standard flu shot, or a placebo. Researchers monitored participants for over a year to see how well the body reacted to the new vaccine and to check for any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NYU Langone Health
New York, New York, 10016, United States
-
Pfizer Clinical Research Unit - New Haven
New Haven, Connecticut, 06511, United States
-
Research Centers of America
Hollywood, Florida, 33024, United States
Conditions
Explore the condition pages connected to this study.